

## 1 **Improving outcomes for children with malaria, diarrhoea and pneumonia in Mozambique through the inSCALE** 2 **technology innovation: A cluster randomised controlled trial**

3  
4 Seyi Soremekun PhD<sup>#∞</sup>, Karin Källander PhD<sup>∞</sup>, Raghu Lingam MD, Ana-Cristina Castel Branco MSc, Neha Batura  
5 PhD, Daniel Strachan PhD, Abel Muiambo MSc, Nelson Salomao MSc, Juliao Condoane MSc, Fenias Benhane MSc,  
6 Frida Kasteng MSc, Anna Vassall PhD, Zelee Hill PhD, Guus ten Asbroek PhD, Sylvia Meek PhD, James Tibenderana  
7 PhD\*; and Betty Kirkwood PhD\*

8  
9 #Corresponding author

10 <sup>∞</sup>Equal first author contribution

11 \*Equal senior author contribution

12 <sup>†</sup>Deceased

- 13 • **Seyi Soremekun**<sup>#∞</sup>, Department of Infection Biology, London School of Hygiene & Tropical Medicine, Keppel  
14 Street, London, WC1E 7HT, United Kingdom. [Seyi.Soremekun@lshtm.ac.uk](mailto:Seyi.Soremekun@lshtm.ac.uk)
- 15 • Karin Källander<sup>∞</sup>, Malaria Consortium, The Green House, 244-254 Cambridge Heath Road, London, E2 9DA,  
16 United Kingdom & Department of Global Public Health, Karolinska Institutet, 17177, Stockholm, Sweden &  
17 UNICEF Programme Division, Health Section, New York, NY, United States. [Karin.kallander@ki.se](mailto:Karin.kallander@ki.se)
- 18 • Raghu Lingam, Population Child Health Research Group, School of Women's and Children's Health,  
19 University of New South Wales. Australia. [r.lingam@unsw.edu.au](mailto:r.lingam@unsw.edu.au)
- 20 • Ana-Cristina Castel Branco Malaria Consortium, Rua Joseph Ki-Zerbo 191, PO Box 3655, Coop, Maputo,  
21 Mozambique [acastelbranco@clintonhealthaccess.org](mailto:acastelbranco@clintonhealthaccess.org)
- 22 • Neha Batura, Institute for Global Health, University College London, 30 Guilford Street, London WC1N 1EH,  
23 United Kingdom. [n.batura@ucl.ac.uk](mailto:n.batura@ucl.ac.uk)
- 24 • Abel Muiambo Malaria Consortium, Rua Joseph Ki-Zerbo 191, PO Box 3655, Coop, Maputo, Mozambique  
25 [a.muiambo@malariaconsortium.org](mailto:a.muiambo@malariaconsortium.org)
- 26 • Nelson Salomao Malaria Consortium, Rua Joseph Ki-Zerbo 191, PO Box 3655, Coop, Maputo, Mozambique  
27 [n.salomao@malariaconsortium.org](mailto:n.salomao@malariaconsortium.org)
- 28 • Juliao Condoane Malaria Consortium, Rua Joseph Ki-Zerbo 191, PO Box 3655, Coop, Maputo, Mozambique  
29 [j.condoane@malariaconsortium.org](mailto:j.condoane@malariaconsortium.org)
- 30 • Fenias Benhane Malaria Consortium, Rua Joseph Ki-Zerbo 191, PO Box 3655, Coop, Maputo, Mozambique  
31 [f.benhane@malariaconsortium.org](mailto:f.benhane@malariaconsortium.org)
- 32 • Frida Kasteng, Department of Global Health and Development, London School of Hygiene & Tropical  
33 Medicine, Keppel Street, London, WC1E 7HT, United Kingdom & Department of Global Public Health,  
34 Karolinska Institutet, 17177, Stockholm, Sweden. [frida.kasteng@ki.se](mailto:frida.kasteng@ki.se)

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

---

<sup>†</sup>Deceased 11 May 2016

- 35
- Daniel Strachan, Institute for Global Health, University College London, 30 Guilford Street, London WC1N  
36 1EH. United Kingdom & The Nossal Institute for Global Health, Melbourne School of Population and Global  
37 Health, The University of Melbourne Victoria, 3010, Australia. [daniel.strachan@unimelb.edu.au](mailto:daniel.strachan@unimelb.edu.au)
  - Anna Vassall, Department of Global Health and Development, London School of Hygiene & Tropical  
38 Medicine, Keppel Street, London, WC1E 7HT, United Kingdom. [Anna.Vassall@lshtm.ac.uk](mailto:Anna.Vassall@lshtm.ac.uk)
  - Zelee Hill, Institute for Global Health, University College London, 30 Guilford Street, London WC1N 1EH,  
40 United Kingdom. [Z.hill@ucl.ac.uk](mailto:Z.hill@ucl.ac.uk)
  - Guus ten Asbroek, Department of Global Health, Amsterdam University Medical Centres, Meibergdreef 9  
42 1105 AZ Amsterdam, The Netherlands and Amsterdam Institute for Global Health and Development,  
43 Paasheuvelweg 25, 1105 BP Amsterdam, The Netherlands. [a.h.tenasbroek@amsterdamumc.nl](mailto:a.h.tenasbroek@amsterdamumc.nl)
  - Sylvia Meek<sup>†</sup>, Malaria Consortium, The Green House, 244-254 Cambridge Heath Road, London, E2 9DA,  
45 United Kingdom
  - James Tibenderana\*, Malaria Consortium, The Green House, 244-254 Cambridge Heath Road, London, E2  
47 9DA, United Kingdom. [j.tibenderana@malariaconsortium.org](mailto:j.tibenderana@malariaconsortium.org)
  - Betty Kirkwood\*, Department of Population Health, London School of Hygiene & Tropical Medicine, Keppel  
49 Street, London, WC1E 7HT, United Kingdom. [Betty.Kirkwood@lshtm.ac.uk](mailto:Betty.Kirkwood@lshtm.ac.uk)
- 50
- 51

---

<sup>†</sup>Deceased 11 May 2016

## 52 **Abstract**

### 53 **Background**

54 The majority of post-neonatal deaths in children under 5 are due to malaria, diarrhoea and pneumonia (MDP). The  
55 WHO recommends integrated community case management (iCCM) of these conditions using community-based  
56 health workers. However iCCM programmes have suffered from poor implementation and mixed outcomes. We  
57 designed and evaluated a technology-based intervention 'inSCALE' (Innovations At Scale For Lasting Effects) to  
58 support iCCM programmes and increase appropriate treatment and other outcomes for children with MDP.

### 59 **Methods**

60 This superiority cluster randomised controlled trial allocated all 12 districts in Inhambane Province in Mozambique to  
61 receive iCCM only (control) or iCCM plus the inSCALE technology intervention. The key components of the  
62 intervention consisted of a digital application on smartphones and tablets providing clinical decision support  
63 algorithms, stock tracking, automatic personalised messaging, free calls, and solar chargers for iCCM-trained  
64 community health workers and primary care facility supervising staff in intervention districts. Population surveys  
65 were conducted at baseline and after 18 months in all districts to assess the impact of the intervention on the  
66 coverage of appropriate treatment for malaria, diarrhoea and pneumonia in children 2-59months of age, on  
67 prevalence of cases of these conditions, and on a range of secondary household and health worker level outcomes.  
68 All statistical models accounted for the clustered study design and variables used to constrain the randomisation. A  
69 meta-analysis of the estimated pooled impact of the technology intervention was conducted including results from a  
70 sister trial (inSCALE-Uganda).

### 71 **Findings**

72 The study included 2740 eligible children in control arm districts and 2863 children in intervention districts. The  
73 prevalence of cases of MDP decreased from 53.5% (1467) to 43.7% (1251) in the control and intervention arms  
74 respectively (risk ratio 0.82, 95% CI 0.78-0.87,  $p < 0.001$ ). The rate of care seeking to the iCCM-trained community  
75 health worker increased in the intervention arm (14.4% vs 15.9% in control and intervention arms respectively) but  
76 fell short of the significance threshold (adjusted RR 1.63, 95% CI 0.93-2.85,  $p = 0.085$ ). Coverage of the appropriate  
77 treatment of cases of MDP increased by 26% in the intervention arm (RR 1.26 95% CI 1.12-1.42,  $p < 0.001$ ) after  
78 accounting for the randomisation and design effects. Across two country trials, the estimated pooled effect of the  
79 inSCALE intervention on coverage of appropriate treatment for MDP was RR 1.15 (95% CI 1.08-1.24,  $p < 0.001$ ).

### 80 **Interpretation**

81 The inSCALE intervention led to a reduction in prevalence of MDP and an improvement in appropriate treatment  
82 when delivered at scale in Mozambique. The programme will be rolled out by the ministry of health to the entire  
83 national CHW and primary care network in 2022. This study highlights the potential value of a technology  
84 intervention aimed at strengthening iCCM systems to address the largest causes of childhood morbidity and  
85 mortality in sub-Saharan Africa.

## 88 **Author Summary**

89 The inSCALE cluster-randomised trial in Mozambique was part of a \$10million project funded by the Bill and Melinda  
90 Gates Foundation to design and test innovative primary care interventions to improve health outcomes for children  
91 with malaria, diarrhoea and pneumonia (MDP), which together are the largest killers of children aged <5yrs. The  
92 study aimed to strengthen the primary health care system with a focus on community health workers, representing  
93 the most accessible level of care for many underserved populations.

94 We designed a technology-based intervention delivered using cheap smartphones. This intervention was based on  
95 mHealth principles and included basic AI to guide correct diagnosis and treatment of MDP, provided personalised  
96 feedback to health workers, and alerts to supervising health facilities on stock outs and data tracking. The study was  
97 implemented within the entire province of Inhambane, and districts were randomly assigned to the intervention or  
98 to continue with standard care (control). Compared to control districts, we observed significant reductions in the  
99 prevalences of MDP in children under 5 years (reductions of 20% for malaria, 34% for pneumonia, and 45% for  
100 diarrhoea) and an increase in appropriate treatment of any cases of MDP by 26% (of all cases MDP) and 40% (of all  
101 children) in the intervention districts.

102 As a result of this trial, the government of Mozambique incorporated the inSCALE intervention into its policy for child  
103 health services, and is in the process of scaling up the programme to all 8000+ community health workers across the  
104 country (2022).

## 105 Introduction

106 More than 5 million mostly preventable deaths occur in children under 5 years of age every year(1). The vast  
107 majority of post neonatal deaths in this group are due to pneumonia, diarrhoea, malaria or malnutrition(2). It is  
108 acknowledged that urgent work is required to address the causes and more widely, the systems within which such  
109 deaths occur. However progress has been uneven; under 5 mortality rates in sub Saharan Africa today remain similar  
110 to or higher than 1990 mortality rates in most high income countries with an average rate of 78 deaths per 1000 live  
111 births across the continent in 2018(2). Lack of access to timely and appropriate clinical management of sick children  
112 is a key factor driving poor health outcomes(3,4) prompting a World Health Organisation/UNICEF joint statement in  
113 2012 advocating for integrated community case management (iCCM) of malaria, diarrhoea and pneumonia delivered  
114 by community-based lay health workers, who would be trained to diagnose and treat key childhood conditions in  
115 areas with poor access to facility-based services (3). In the decade following this statement, iCCM programmes have  
116 been introduced into more than 50 low- and middle-income countries (LMICs)(5–7). Whilst a recent multi-country  
117 modelling study in DRC, Malawi, Niger, and Nigeria (8) estimated that iCCM may have been responsible for averting  
118 nearly 5000 deaths per year in these countries combined due to malaria, diarrhoea and pneumonia, this estimate  
119 varied considerably between countries, and was in contrast to a Cochrane systematic review which found no clear  
120 impacts of iCCM on morbidity and mortality(9). Both studies reported poor or uneven implementation of iCCM  
121 programmes and a need for further studies that addressed structural deficiencies in health systems and processes  
122 that hamper success and scale-up.

123 Central to the challenge in implementation of iCCM has been the lack of sufficient support for community-based  
124 health worker (CHW) networks, low rates of CHW attrition, of reported motivation, and of quality of disease  
125 management practices(10). The WHO calls for “innovative and tailored approaches” to strengthening child health  
126 services (1), yet there are few programmes or even research studies which have explicitly addressed structural  
127 barriers in the context of scaling up iCCM effectively.

128 Digital technologies, and specifically mHealth (the use of mobile technologies in medical and public health practice  
129 (11) is an area of growing interest for the delivery of health services in sub-Saharan Africa (12,13) particularly given  
130 the rapid expansion of mobile phone networks and usage in this setting (14). In this paper we report on the  
131 evaluation of a systems-strengthening package of programmes collectively called “inSCALE” (interventions at scale  
132 for community access and lasting effects). inSCALE was a multi-country study of innovative interventions  
133 implemented by the Malaria Consortium in partnership with the governments of Mozambique and Uganda and  
134 supported by international funders (the Bill and Melinda Gates Foundation, UNICEF, and the Canadian international  
135 Development Agency now Global Affairs Canada (GAC)) . Reported in this paper is findings of the “inSCALE  
136 technology intervention”, a disease management support package that included electronic clinical decision  
137 algorithms, personalised reports, messaging, and feedback to CHWs and health facility staff. The Mozambique site  
138 tested the inSCALE technology intervention only; the Uganda site tested both the technology intervention and a  
139 community-based intervention described elsewhere [[Uganda ref](#)]. The technology interventions in both countries  
140 sought to specifically address primary health system challenges that could strengthen provision for key childhood  
141 illnesses through improving CHW performance, motivation and reducing attrition. The primary aim of the trial was to

142 assess the impact of the inSCALE technology intervention on the coverage of the appropriate treatment of childhood  
143 malaria, diarrhoea and pneumonia. This paper reports on the impacts of the technology intervention in Mozambique  
144 to accompany the separate impact analysis for the Uganda inSCALE trial [ref] and conducts a meta-analysis of pooled  
145 impact of the technology intervention across its sites in Uganda and Mozambique.

## 147 **Results**

148 In total 9231 households in the 12 districts were assessed for eligibility and of these, 495 were empty or no one was  
149 home, and 4483 did not contain children under 5 years of age. Overall, the main caretaker was available in 92%  
150 (3920) of houses with children under 5 years of age. At the endline survey, a total of 2718 children had had  
151 symptoms of MDP in the past month (the impact analysis sample), of which 1467 were in the control arm and 1251  
152 in the intervention arm (Figure 1 flow chart). Household characteristics of sick children were fairly well balanced  
153 between arms with small variations in some parameters – Table 1.

154 The restricted randomisation method resulted in good balance between intervention arms for balance variables as  
155 described in the protocol paper(15), which were care seeking rates, CHW motivation, and cost of seeking care (Table  
156 2). Differences for all variables was either less than 5% (percentages), or less than 0.1 (means).

**Table 1.** Characteristics of the inSCALE Mozambique study sample

Characteristic	Control % (n)	Technology % (n)
<b>Eligible children</b>	<b>N = 2740</b>	<b>N = 2863</b>
% children with MDP	53.5% (1467)	43.7% (1251)
% children with suspected malaria*	48.5% (1300)	39.8% (1118)
% children with confirmed malaria*	24.6% (661)	21.8% (612)
% children with diarrhoea**	7.2% (198)	4.2% (121)
% children with suspected pneumonia**	16.2% (443)	10.6% (304)
<b>Children with MDP</b>	<b>N = 1467</b>	<b>N = 1251</b>
% Respondent is mother of sick child	81% (1181)	83% (1036)
% children are boys	50% (733)	50% (629)
<b>Age of mother</b>		
12-19	10% (144)	8% (104)
20-29	38% (552)	37% (467)
30-39	28% (413)	30% (373)
40-49	12% (181)	14% (175)
50+	8% (113)	6% (76)
Not known	4% (64)	4% (56)
<b>Highest education level completed (respondent)</b>		
None	31% (453)	32% (400)
Incomplete primary	48% (706)	45% (557)
Primary or higher	21% (308)	24% (294)
<b>Mother tongue</b>		
Bitonga	17% (246)	6% (81)
Chitsua	54% (793)	72% (900)
Chichopi	17% (254)	19% (242)
Other	12% (174)	2% (28)
<b>Marital status</b>		
Married	2% (34)	3% (41)
Living with partner (not married)	78% (1151)	74% (929)
Single/divorced/widowed	19% (282)	22% (281)
<b>% Main occupation is farming/fishing</b>	<b>75.9% (1113)</b>	<b>64.0% (801)</b>

\*Denominator is the 5490 children aged 4months – 5 years; \*\*Denominator is the 5603 children aged 2m – 5 year

160

161 **Table 2.** Key indicators used to balance arms at baseline

<b>Variables included in the restricted randomisation*</b>	<b>Control arm 662 children with MDP XX CHWs</b>	<b>Technology 658 children with MDP XX CHWs</b>	<b>Difference</b>
Mean ( $\log_{10}$ ) cost of care seeking for children with MDP (SD)	1.11 (0.09)	1.14 (0.14)	0.03
Cluster mean % care seeking to an CHW for children with MDP (SD)	22.5% (23.03)	22.8% (16.92)	0.26
Cluster mean % care seeking to a public facility for children with MDP (SD)	50.96% (21.63)	48.79% (14.80)	2.17
Cluster mean CHW motivation score (SD)	2.29 (0.46)	2.38 (0.50)	0.09

162

\*Outcomes are presented as mean percentages or mean costs across all clusters in each arm



163

164 **Intervention coverage, sickness and care seeking**

165 By the end of the 18-month implementation period, 68% of CHWs reported having a working inSCALE phone and  
166 app, and 45% had sent a report via the app in the last 4 weeks (Table 3). Whilst overall prevalence of MDP was  
167 similar between arms at baseline, there were significant reductions in the prevalence of suspected malaria,  
168 diarrhoea and pneumonia (reductions ranging from 18% to 45%), and a 16% increase in the prevalence of diagnostic  
169 testing for malaria in the intervention arm at endline (Table 4). Care seeking to the CHW as the first port of call was  
170 14.4% in the control arm and 15.9% in the intervention arm (199/1251). After accounting for the restricted  
171 randomisation and clustered design this represented a 63% increase in care-seeking to the CHW, a result that just  
172 fell short of significance (Table 5,  $p=0.085$ ). There were no significant differences in care seeking rates to other  
173 providers or in the prevalence of children for whom no care was sought (Table 5).

174 **Table 3.** Exposure to intervention components recorded during the endline survey

Intervention component	Technology
CHWs	N=104
% CHWs had a working phone and inSCALE app at endline (n)	68% (69)*
% CHWs submitted at least one inSCALE report through their phone in the last 4 weeks	45.2% (44)*

175 \*data missing for 3 CHWs

177 **Table 4.** Prevalence of suspected malaria, diarrhoea and pneumonia (MDP) and blood tests for malaria in children under 5 years at baseline and endline

Prevalence of	Baseline (reported prevalence in last 2 weeks)		Endline (reported prevalence in last 4 weeks)		Impact of inSCALE at endline Risk ratio inSCALE/control RR: 95% CI; p*
	Control arm	Technology arm	Control arm	Technology arm	
Any of MDP	29.3% (662/2257)	30.4% (658/2165)	53.5% (1467/2740)	43.7% (1251/2863)	<b>0.82</b> (0.78-0.87) p<0.001
Suspected malaria*	25.9% (562/2171)	26.7% (556/2084)	48.5% (1300/2682)	39.8% (1118/2808)	<b>0.80</b> (0.72-0.89) p<0.001
Blood test for malaria**	31.7% (200/631)	29.5% (181/613)	59.7% (937/1570)	62.3% (831/1335)	<b>1.16</b> (1.06-1.28) p=0.002
Confirmed malaria***	65.5% (131/200)	68.5% (124/181)	70.5% (661/937)	73.7% (612/831)	<b>1.04</b> (0.92-1.18) p=0.514
Diarrhoea	5.1% (116/2257)	5.3% (114/2165)	7.2% (198/2740)	4.2% (121/2863)	<b>0.55</b> (0.42-0.71) p<0.001
Pneumonia	9.9% (223)	11.8% (256/2165)	16.2% (443/2740)	10.6% (304/2863)	<b>0.66</b> (0.44-0.99) p=0.045

178 Prevalence (n/N) calculated as total eligible children 2 months-59 months of age (N) with condition in question (n), with the exception of fever and malaria where age range is 4 months-59 months in line with treatment guidelines.

179 \*Fever, excludes fevers with a negative blood test for malaria. \*\*denominator includes all children reporting fever in the last two (baseline) or 4 (endline) weeks. \*\*\*percentage of all blood tested fevers that were positive. \*Adjusted for  
180 i) parameters used to balance arms at baseline and ii) the baseline prevalence of prevalence parameter182 **Table 5.** Care seeking choices for children with MDP at endline

Outcome % of children (n)	Control (N=1467)	Technology (N=1251)	Risk ratio tech/control RR: 95% CI	p
% seeking care at a CHW (first point of call)	14.4% (211)	15.9% (199)	1.63 (0.93-2.85)	0.085
% seeking care at a CHW (at any point)	14.7% (215)	16.2% (203)	1.61 (0.91-2.85)	0.104
% Not seeking care outside the home	18.3% (269)	20.6% (251)	0.98 (0.74-1.30)	0.898
% seeking care at a public facility (at any point)	67.4% (988)	63.7% (797)	1.11 (0.93-1.33)	0.253
% seeking care in the private sector (at any point - private facility, pharmacy, shop, herbalist etc)	3.6% (53)	2.4% (30)	0.94 (0.51-1.71)	0.839

184 **Appropriate Treatment**

185 Baseline levels of appropriate treatment were similar for the combined MDP endpoint but varied by provider and for  
186 individual conditions between intervention arms (Table 6b). At endline there was an 26% increase in appropriate  
187 treatment of cases of MDP (the primary outcome (Table 6a) in the inSCALE arm compared to the control arm (95%  
188 confidence interval: 12%-42%,  $p < 0.001$ ). This rose to 30% when only episodes treated with recommended first line  
189 treatments were defined as appropriately treated (Table 6a 95% CI: 12%-52%,  $p = 0.001$ ). A breakdown of  
190 appropriate treatment by provider suggests this impact was driven by significant improvements in appropriate  
191 treatment coverage in public health facilities (Table 6a) which were the first port of call for caregivers for more than  
192 60% of sick children in both arms (Table 5), and in the appropriate treatment of diarrhoea, where a 76% increase  
193 (95% CI 20%-256%  $p = 0.003$ ) in the use of oral rehydration salts was observed in the intervention arm (Table 7). Note  
194 it was not possible to estimate a confidence interval for use of ORS plus zinc due to small cell sizes. Additional  
195 improvements came in the use of the recommended first line antibiotic for pneumonia (50% increase in prescribing  
196 of amoxicillin in the intervention arm 95% CI: 3%-217%). A whole-child analysis (Supplementary File 1 Table S6)  
197 estimated an improvement of 40% in the proportion of children appropriately treated for all MDP condition(s)  
198 reported in the last 4 weeks in the intervention arm (95% CI: 9% - 79%  $p = 0.009$ ).

199

200 **Table 6a.** Appropriate treatment: Appropriate treatment of episodes suspected malaria, diarrhoea or suspected pneumonia (MDP)

Appropriate treatment	Control		Technology		Technology v Control**	
	%	n/N*	%	n/N*	RR (95% CI)	p
Any episode of MDP	<b>47.8%</b>	<b>928/1941</b>	<b>50.7%</b>	<b>782/1543</b>	<b>1.26 (1.12-1.42)</b>	<b>&lt;0.001</b>
Any episode of MDP (first line treatments only)***	<b>42.2%</b>	<b>819/1941</b>	<b>48.2%</b>	<b>744/1543</b>	<b>1.30 (1.12-1.52)</b>	<b>0.001</b>
<b>Appropriate treatment by first care seeking location (any episode of MDP)</b>						
CHW	49.5%	146/ 295	61.9%	148/239	1.04 (0.86-1.25)	0.675
Public Facility	58.0%	736/1269	62.2%	594/955	1.26 (1.07-1.48)	0.004
Private sector (private facility, pharmacy, shop, herbalist)	29.4%	10/34	21.7%	5/23	1.66 (0.52-5.34)	0.392
No care seeking outside of the home	10.5%	36/343	10.7%	35/326	1.23 (0.75-2.00)	0.408

201 \*N=total episodes of the described disease; n=total episodes where the correct drugs were received

202 \*\*adjusted for baseline levels of appropriate treatment for the condition(s) in question, and for variables used to balance arms at baseline (rates of facility and CHW care seeking, cost of care seeking, and CHW  
203 motivation score)

204 \*\*\* First line treatments: artemisinin combination therapy for malaria, ORS for diarrhoea, and amoxicillin for pneumonia

205

206

207  
 208  
 209  
 210  
 211  
 212

**Table 6b.** Primary Outcome at baseline: Percentage of episodes of MDP appropriately treated

Outcome	Control	Technology
	% (n/N*)	% (n/N*)
<b>Total children in baseline sample</b>	<b>2257</b>	<b>2165</b>
<b>% children with MDP**</b>	29.3% (662/2257)	30.4% (658/2165)
<b>Appropriate treatment</b>		
<b>Any episode of MDP</b>	<b>33.1% (298/901)</b>	<b>28.2% (261/926)</b>
Suspected malaria	31.3% (176/562)	28.4% (158/556)
Confirmed malaria	90.1% (118/131)	88.7% (110/124)
Diarrhoea (ORS)	56.0% (65/116)	44.7% (51/114)
Diarrhoea (ORS and zinc)	2.6% (3/116)	2.6% (3/114)
Pneumonia (any antibiotic)	25.6% (57/223)	20.3% (52/256)
Pneumonia (amoxicillin)	10.3% (23/223)	10.6% (27/256)
Any episode of MDP at the CHW (first care seeking location)	35.7% (71/199)	32.0% (70/219)
Any episode of MDP at the Public Facility (first care seeking location)	46.8% (214/457)	38.1% (171/449)
Any episode of MDP at the Private sector (first care seeking location, includes private facility, pharmacy, shop, herbalist)	18.8% (3/16)	19.2% (5/26)
Any episode of MDP - no care seeking outside of the home	10.1% (22/209)	6.2% (14/226)

\*N=total episodes of the described disease; n=total episodes where the correct drugs were received. \*\*MDP: denominator includes all children with suspected or confirmed malaria, diarrhoea or pneumonia

213

214

215 **Table 7.** Impact of the inSCALE intervention on appropriate treatment by condition

Outcome	Control arm	Technology arm		
	Freq (%)	Freq (%)	risk ratio versus control (95% CI)	p
<b>Appropriate treatment by condition</b>				
Suspected malaria	54.4% (707/1300)	56.6% (633/1118)	1.08 (0.97-1.20)	0.150
Confirmed malaria	96.4% (637/661)	96.2% (589/612)	1.02 (0.99-1.04)	0.221
Diarrhoea (ORS)	29.3% (58/198)	43.8% (53/121)	1.76 (1.20-2.56)	0.003
Diarrhoea (ORS + zinc)	0.0% (0/198)	1.7% (2/121)	-	-
Suspected pneumonia (any antibiotic)	36.8% (163/443)	31.6% (96/304)	0.80 (0.60-1.08)	0.142
Suspected pneumonia (amoxicillin)	12.2% (54/443)	19.1% (58/304)	1.50 (1.03-2.17)	0.033

216

217

218 **CHW motivation, identification, clinical knowledge, attrition, and stockouts**

219 The mean motivation and the mean social identification scores were relatively high and did not differ between arms  
 220 (difference in motivation factors score: -0.03 95% CI -0.57, 0.51; difference in identification factor score: 0.01 95% CI  
 221 -0.42, 0.43). CHW attrition rates were approximately 18%-19% in both intervention arms with no detected difference  
 222 (Table 8). Overall scores for CHW clinical knowledge of the signs and management of MDP, also did not differ  
 223 significantly between arms (Table 8). A breakdown of CHW knowledge scores by condition suggests a trend of  
 224 improved knowledge in technology arm CHWs particularly in diagnosing pneumonia and diarrhoea - though none  
 225 reached the threshold for statistical significance and may be chance findings (Table S3 in supplementary file 1).  
 226 There were no between-arm differences in the rate of stockouts for key MDP treatments in the previous 3 months,  
 227 though overall rates of stockouts were fairly high at >50% (Table 8).

228

229 **Table 8.** Community health worker (CHW) outcomes: Stockouts, attrition, motivation and knowledge in control and intervention  
 230 arm clusters

Outcome	Control arm (N = 103)	Technology arm (N = 104)	Effect size (95% CI)	p
	Mean (sd)	Mean (sd)		
% CHWs experienced a stockout of any MDP drug in last 3 months*	52.4% (54)	56.7% (59)	RR: 1.17 (0.92-1.49)	0.207
Mean CHW motivation score	4.6 (0.5)	4.7 (0.5)	RD: -0.03 (-0.57, 0.51)	0.914
Mean CHW social identification score	4.7 (0.6)	4.8 (0.5)	RD: 0.01 (-0.42, 0.43)	0.976
Mean CHW knowledge score	19.7 (4.3)	19.8 (4.4)	RD: 0.97 (-2.01, 3.94)	0.524
Proportion CHW attrition (%)	18.4% (13.6)	18.5% (10.0)	RD: 1.31 (-18.66, 21.30)	0.878

231 \* Stockouts of any of artemisinin combination therapy, amoxicillin, or ORS. RR- risk ratio; RD- risk difference

232 **Sensitivity analyses and robustness tests**

233 Sensitivity tests were conducted with two alternative definitions of appropriate treatment: i) only including children  
 234 with a positive malaria diagnostic test, and ii) including quinine as an appropriate treatment for malaria to account  
 235 for its use as a second line treatment or during in-patient care (S2 Table in the in Supplementary File 1). Both showed  
 236 a trend of improved coverage of overall appropriate treatment (20% an 14% improvement, p values 0.006 and 0.073  
 237 respectively for i) and ii)). We performed robustness tests of the key primary and secondary impact outcomes  
 238 appropriate treatment, care seeking, CHW motivation, social identity, clinical knowledge, stockouts, and attrition by  
 239 repeating the analyses using a comparison of cluster-level mean outcomes (S4 Table in Supplementary File 1). This  
 240 approach estimated similar significant improvements in appropriate treatment as the random effects model with the  
 241 exception of the increase in care seeking to CHWs which did not reach significance.

242

243

244


245 **Meta-analysis of appropriate treatment for MDP: Uganda and Mozambique**

246 Figure 2 shows the results of a fixed effects meta-analysis of the risk ratios (RRs) for percentage coverage of  
247 appropriate treatment in Uganda and Mozambique. The analysis suggests implementation of the inSCALE technology  
248 model could improve appropriate treatment by 15% (8% - 24%) overall.

249



250 **Figure 1.** Flow diagram of participant progression through trial phases. Final analysis sample: children aged 2 months to 5 years with suspected malaria, diarrhoea or  
 251 suspected pneumonia (MDP). \* Maxixe and Inhambane, the economic and provincial capitals were excluded from the study (do not implement iCCM).



255

256

257 **Figure 2.** Forest plot displaying an inverse-variance weighted fixed-effect meta-analysis of the effect of the inSCALE technology interventions on appropriate treatment of episodes of  
258 suspected malaria, diarrhoea or suspected pneumonia (Uganda and Mozambique). Effect size (ES) is the risk ratio for appropriate treatment.

259

260

261

262

263

264

265

266

267

268

269


270

271

272

273

274



275

276

Fixed effects meta analysis (country = fixed effect) Appr. Treat = appropriate treatment of illness episodes (suspected malaria, diarrhoea or suspecper pneumonia). I = intervention arm, C = control arm. ES = baseline-adjusted risk ratio (effect size) of % episodes MDP appropriately treated in intervention versus control arm.

## 277 Discussion

278  
279 We have demonstrated that a scalable, innovative technology-based intervention implemented in Mozambique can  
280 meaningfully improve the coverage of appropriate treatment for common childhood illnesses covered by the iCCM  
281 programme by 26-30%. We further showed in a meta-analysis of two countries (Mozambique and Uganda)  
282 implementing similar technology-based interventions that an 8-24% improvement in appropriate treatment is likely  
283 achievable elsewhere. Our results suggest that iCCM programmes can contribute to the quality of care provided by  
284 primary health services by the use of relatively inexpensive technology that prioritises support, efficiency and  
285 performance. As a result of this work, the government of Mozambique has expanded the inSCALE technology  
286 intervention to seven out of eleven provinces with over 2,500 CHWs and 299 supervisors using the app to date. The  
287 programme will be rolled out to all 8,800 CHWs and 1,300 supervisors nationally by end of 2022 and a full data  
288 integration plan with DHIS2 is ongoing to optimize strategic decision making(16,17). The expanded programme  
289 name, upSCALE, reflects the successful and rapid uptake of our research into national policy and the creation of a  
290 national CHW mHealth system(17).

291 Our conceptual framework for the design of the inSCALE innovation expected that differences in CHW motivation,  
292 attrition and social identification would be one of the drivers of improvement in appropriate treatment(15,18). As  
293 noted in our formative research and in other settings, ownership of local programmes can be fragmented, CHW  
294 interventions are often only tenuously linked with the wider health system and therefore poorly supervised, and  
295 their contribution under-recognised(19). The CHWs we surveyed however were in general highly motivated and  
296 reported a strong degree of connectedness to the wider health system in both arms at baseline and at the end of  
297 follow-up. Local facility records estimated CHW attrition was moderate at 18% over the implementation period and  
298 did not differ by intervention arm. Our findings suggest that in contrast to our conceptual framework, alternative  
299 routes to impact may be more important in this setting. Though coverage of appropriate treatment in children taken  
300 to the CHW was similar across arms, we observed the largest overall increase in coverage of appropriate treatment  
301 occurred at public health facilities and in children with diarrhoea, very similar to the pattern of impact observed in  
302 the sister inSCALE trial in Uganda [ref]. That these patterns were largely consistent across two countries with  
303 separate intervention design and implementation teams is a persuasive indicator of the alternative impact pathways  
304 and mechanisms of impact through which inSCALE operates - and warrants further exploration in future studies. This  
305 nonetheless likely highlights the integrated nature of inSCALE intervention whereby training and usage of the app by  
306 both CHWs and supervising staff at primary care facilities will have increased health worker exposure to guideline-  
307 led recommendations for disease management, alerts for low CHW stock for key commodities, motivational  
308 messaging, and reporting on prevalence of key childhood conditions. Diarrhoea in particular is often perceived  
309 simply as a symptom of a more highly prioritised condition on which treatment is focused(20) and may therefore be  
310 overlooked by health workers even if ORS is available (20–22). These findings point to the gains that may be made by  
311 adopting an approach that not only strengthens community based iCCM programmes, but the linked primary health  
312 care system.

313 Coverage of the inSCALE innovation after 18 months of follow-up was moderate to good (68% CHWs had a working  
314 phone and inSCALE app and 45% had sent a report in the last month). It is difficult to assess this intervention  
315 coverage rate in context of similar interventions due to the variability in intervention components, and in endpoint  
316 definitions. A SMS (short message service) message-based randomised controlled trial in Tanzania delivered 7  
317 messages to drug shop vendors with recommendations for correct treatment of malaria and reported 70% of  
318 dispensers received at least 75% of the intended SMS messages. Whilst this appears comparable to our reported  
319 rates, the difference in the health provider type and in the content of the intervention precludes a direct comparison  
320 (23). Nonetheless a review of a selection of trials of child health-based mHealth interventions in low and middle  
321 income country settings (LMICs) report widely varying intervention coverage rates between 24% and 85% (24,25).  
322 Lack of medicinal stock for common childhood conditions has been a barrier to prompt and appropriate treatment in  
323 other settings(26), and affected our study sites in Mozambique during and after the period of implementation (8,19).  
324 Key issues were the national stock outs of key malaria and antibiotic medications and diagnostic tests within the last  
325 6 months of the study, which may have suppressed the full potential impact of the technology intervention for these  
326 outcomes. Research by Save the Children in this setting suggests that households who were aware of stockouts at  
327 the iCCM CHW may go elsewhere for treatment(19). More than 50% of CHWs across both arms reporting at least  
328 one stockout of supplies for the management of MDP in the previous 3 months; such commodity supply barriers  
329 were outside the control of our intervention nonetheless it was encouraging that our results highlight a positive  
330 impact of the inSCALE app in maintaining or improving overall coverage of clinical management for pneumonia and  
331 diarrhoea despite these persistent issues and moderate intervention coverage.

332

### 333 **Wider implications on case prevalence, fatality, productivity, user costs and transmission**

334 The highest case fatality rates for pneumonia, malaria and diarrhoea occur in sub-Saharan Africa(27,28) Separate  
335 cost-effectiveness studies for the inSCALE trials in Uganda and Mozambique [ref] estimate that increasing coverage  
336 of appropriate treatment will have a modest impact on child deaths (1-5%). However important proximal outcomes  
337 of such interventions include a potential to reduce community transmission of causative pathogens and/or the risk  
338 of recurrent MDP infections (29) and lowering cost of care seeking and increasing equitable access to care (22)  
339 through the strengthening and raised profile of iCCM-trained CHWs. Reduced community transmission in particular  
340 was suggested by the decrease in prevalence of MDP both over time across the study site in Mozambique, and the  
341 additional significantly faster fall prevalence in the intervention arm districts. There is a plausible route to this effect  
342 through the increase in the timely use of medications, and/or in awareness of preventative measures (30,31). The  
343 reduction in disease prevalence, and improvement in appropriate treatment for diarrhoea and pneumonia are  
344 particularly to be welcomed considering no single preventative intervention may be easily applied to control these  
345 diseases as a result of their multiple pathogen aetiology(32).

346 Our study had several limitations. Our estimates of prevalence of MDP and appropriate treatment were based on  
347 caregiver reports which may be subject to misclassification. Studies of caregiver recall for pneumonia and malaria  
348 symptoms have sensitivities and specificities in the range of 31%-91% depending on the setting(33,34).

349 Recommended strategies to improve the accuracy of disease and treatment estimates include setting the length of  
350 the recall period to four weeks (versus 2 weeks used in the inSCALE baseline survey), the use of pictures of available  
351 treatments to respondents and the development of survey questions which prioritise local terms and are based on  
352 well-validated survey instruments(33–35) including the United Nations- and USAID-supported Multiple Indicator  
353 Cluster Survey and Demographic Health Surveys(36,37). We incorporated all these strategies in our surveys and  
354 used tailored definitions of disease and treatments in line with national guidelines, including the presumptive use of  
355 ACT to treat fever, a practice compounded by nationwide stockouts of iCCM drugs and tests at the time. Our  
356 sensitivity analyses of the main outcome with alternative definitions of appropriate treatment [see Table  
357 supplementary file 1] nonetheless produced similar results – of note, restricting cases of fever to those with a  
358 confirmed malaria test estimated a 20% improvement in appropriate treatment which remained highly significant.  
359 The inSCALE study evaluated the impact of strategies to improve scale-up and coverage of iCCM programmes using a  
360 randomised controlled design as we believed this method would provide the most convincing effectiveness  
361 estimates for stakeholders. The number of district clusters available for randomisation was however determined by  
362 iCCM programme readiness (iCCM-trained CHWs in place) and lack of concurrent interventions in the area at  
363 baseline. This resulted in twelve districts available for randomisation. We tested the robustness of our random-  
364 effects models with cluster-averaged t-tests of our primary outcomes as recommended by Hayes and Moulton(38),  
365 and whilst less powerful, we observed similar estimates of impact on appropriate treatment (See supplementary file  
366 1).

## 367 **Conclusions**

368 The body of research evidence for digital and mHealth programmes is increasing, however there remains a  
369 significant gap for evidence from good quality studies of the potential for available and emerging technologies to  
370 transform health outcome in LMICs for children, particularly when delivered via community-based health worker  
371 cadres(39). Mobile phone penetration is predicted to increase in sub-Saharan Africa(40) and is estimated to be a key  
372 medium by which health care access and service delivery can be improved for the underserved. The WHO's recently  
373 published set of global recommendations for digital interventions for health services delivery highlight the potential  
374 of mHealth interventions for a range of uses and includes the key components of the inSCALE technology  
375 intervention – clinical decision support, stock tracking and provider-to-provider telemedicine (41). Significantly, the  
376 2019 WHO/UNICEF iCCM strategy meeting in Addis Ababa recommended “Interventions to improve quality,  
377 including supportive supervision and mentoring of CHWs in designated health facilities, are essential to ensure high-  
378 quality iCCM and should be budgeted for and included in district plans”(42). This renewed encouragement for  
379 implementation of iCCM this decade may encourage relevant stakeholders looking to efficiently scale up  
380 programmes to explore digital solutions for their context. Our study and meta-analysis together with the expansion  
381 of the inSCALE programme in Mozambique (16,17) highlight the potential scalability of an mHealth intervention  
382 aimed at strengthening iCCM systems to address the largest causes of childhood morbidity and mortality in sub-  
383 Saharan Africa.

384

## 385 **Materials and Methods**

### 386 **Study Site**

387 The study took place in the Inhambane Province of southern Mozambique between November 2013 and July 2016.  
388 The province covers a geographical area of 68,775km<sup>2</sup> with a population of approximately 1.4 million of which 17%  
389 are under 5 years of age(43). The Inhambane mortality rate in this age group at the start of the study was 76.4  
390 deaths per 1000 livebirths(44), with more than 60% of all deaths in the province caused by a combination of malaria,  
391 diarrhoeal diseases and pneumonia(45,46). Since 2011, iCCM had been included in the Inhambane programme of  
392 work for Agentes Polivalentes Elementares (APE), the name for the local cadre of community health worker and  
393 referred to as CHWs in this paper. Government and donor funding for the programme supported the training,  
394 supervision and provision of iCCM commodities for all CHWs in the province throughout the study period. A detailed  
395 study protocol for the inSCALE trial in Mozambique has been published elsewhere(15). Details of the setting and  
396 study design for the inSCALE study in Uganda, used for the metanalysis presented in this paper, is published  
397 elsewhere [[ref](#)].

### 398 **Study Design and Participants**

399 We conducted a superiority open label two-arm cluster-randomised controlled trial in 12 districts in Inhambane  
400 Province in southern Mozambique. Six districts (Funhalouro, Govuro, Jangamo, Panda, Vilankulo, and Zavala) were  
401 randomised to the inSCALE intervention and six (Homoine, Inharrime, Inhassouro, Mabote, Massinga, and  
402 Morrumbene) to the control arm. The provincial and economic capitals of Inhambane, Inhambane and Maxixe  
403 respectively, was excluded from the randomisation and Maxixe was instead used for piloting of the intervention in  
404 its rural areas during the design stage. Intervention allocation was randomised at the district level as this was the  
405 lowest unit of administration and training for the CHW iCCM programme and therefore for implementation of the  
406 inSCALE intervention. Eligible households within the district were defined as those with at least one resident child  
407 under five years of age at any point during the study in a community served by at least one iCCM-trained CHW. Local  
408 data collected by Malaria Consortium in the area in 2011 suggested that 45% of households within each community  
409 fit the eligibility criteria.

410 Ethical approval for the study was obtained from the Mozambique National Bioethics Committee for Health  
411 (reference 345-CNBS-10) and the London School of Hygiene & Tropical Medicine Ethics Committee in the UK  
412 (reference 5762). Approval for the random allocation of districts to intervention or control groups and  
413 implementation of the interventions was obtained from the Inhambane Provincial Office responsible for health  
414 administration for the province. Written informed consent was obtained from the main caregiver of each child under  
415 5 years of age for baseline and follow up data collection. Consent forms included an explanation of the purpose of  
416 the data collection and confirmed participants were free to withdraw at any time. The inSCALE trial is registered on  
417 [clinicaltrials.gov](https://clinicaltrials.gov) with identifier NCT01972321.

418

## 419 **Randomisation and Blinding**

420 In order to reduce the likelihood of chance imbalances between intervention arms at baseline given the number of  
421 clusters available for randomisation(38,47)., we performed a randomisation that was restricted with respect to the  
422 percentages of households with sick children seeking care at a public health facility, the percentage seeking care to a  
423 CHW, average CHW motivation (composite) score and the log cost of care seeking for sick children. Data for these  
424 parameters was obtained from a baseline survey conducted between November- December 2012. We used the  
425 statistical software Stata (version 13) to generate the 924 possible randomisation schemes for the 12 districts and  
426 picked one at random from the subsection of 84 schemes that fitted our balance criteria(48) [see online supplement  
427 file 1]. Due to the nature of the technology intervention, it was not possible to blind participants or fieldworkers to  
428 the intervention allocation, however allocation was masked in the database and all analyses were initially performed  
429 on data with intervention allocation removed and repeated on unblinded data after agreement on the final analysis  
430 methods with study partners.

## 431 **Study Procedures – data collection**

432 The baseline survey was conducted in all households in 2-8 randomly-selected communities (known as enumeration  
433 areas or EAs) sampled proportional to size in each district in order to cover approximately 500 households per  
434 district (mean of 91 households per village), which would provide 80-90% power to detect an impact of the  
435 intervention in accordance with the estimated sample sizes for detecting intervention impact at endline as described  
436 in the inSCALE protocol paper(15). Approximately 21 CHWs were also surveyed per district at baseline (1-2 per  
437 village). Community sampling frame data were based on complete enumeration information provided by the District  
438 Offices and EA location, size and households were verified by field workers.

439 The baseline survey was administered to caregivers of children under 5 years of age, and collected information on  
440 symptoms of malaria, diarrhoea, and pneumonia (MDP) in these children in the last 4 weeks, care seeking for these  
441 illnesses, costs of care, socioeconomic data at the household level. Household questionnaires were based on  
442 standard health survey instruments used in the country (Mozambique DHS(36) and Malaria Indicator Cluster  
443 Surveys(37)). The CHW survey included data on CHWs' clinical knowledge, time use, motivation and 'social identity' –  
444 or sense and degree of connectedness to the local and national CHW and health services systems. The CHW clinical  
445 knowledge instrument was developed based on the format and example clinical event scenarios in the WHO Health  
446 Facility Survey Tool template (49). The likert scale-based CHW motivation and identity tool used a pictorial scale  
447 indicating degree of agreement with statements about enthusiasm for the job, motivation and identification with the  
448 local and national iCCM programme, and was developed based on extensive formative research by the study team  
449 on health worker motivation and social identity (50,51). Both tools were adapted to the Mozambique setting prior to  
450 usage with the input of facility staff and CHWs in an iterative process that developed wording, accompanying  
451 graphics and reference to local health system structures and clinical guidelines.

452 Household and CHW surveys were also extensively field piloted with field staff including workshops role playing and  
453 refining of translations, and all tools were delivered in Portuguese. A quality control check of 10% of the weekly

454 survey households was undertaken by field worker supervisors. Pictures of locally available medications were used in  
455 the household surveys to improve the accuracy of reports of treatment for MDP(33).

456 At the end of the follow-up period an endline impact survey was conducted in May-June 2015 in the same villages  
457 visited at baseline in households with children meeting inclusion criteria at endline, and again covering all active  
458 CHWs serving the selected villages. The survey collected data across the same themes to estimate study impact and  
459 included additional questions to CHWs and caregivers on coverage of the inSCALE innovation components in the  
460 intervention arm. All household and CHW data collection tools are available in Supplementary File 2.

## 461 **Intervention**

462 The inSCALE technology intervention was developed in collaboration with Dimagi a social enterprise corporation  
463 focused on the development of digital solutions for health workers in low and middle income settings (52). Steering  
464 and input was received from the Mozambique ministry of health, community and facility-based stakeholders,  
465 funding bodies and the inSCALE trial steering committee(15,53). The aim of the innovation was to leverage  
466 technological strategies to strengthen links between fragmented CHW programmes and the primary care health  
467 services including links between CHW peers and health facility staff, and by doing so to improve CHW outcomes and  
468 child health outcomes for children. The inSCALE technology intervention development process and conceptual  
469 framework linking intervention components, outputs and outcomes is described in detail in the protocol paper (15).  
470 The technology intervention was implemented in July 2013, and after a 6 month roll-out and embedding period,  
471 follow-up to impact analysis continued to July 2015 (18 months). iCCM-trained CHWs and their health facility  
472 supervisors in the intervention arm were provided with a Samsung® smartphone installed with the inSCALE mHealth  
473 application, a solar charger with a number of pin adapters, and a solar lamp for night-time consultations.  
474 Intervention arm CHWs and health facility supervising staff were trained in the use of the mHealth tools. Training  
475 was conducted using a cascade approach where 7 master trainers trained 18 facility- and community-based trainers  
476 who in turn trained 47 health facility supervisors and 132 CHWs in the technology arm over 4 days with follow-up  
477 support provided by the project team during the implementation period. The inSCALE mHealth mobile app  
478 consisted of a sick child decision support algorithm in a user-friendly interface including multimedia, audio and  
479 images to improve adherence to iCCM treatment protocols. CHWs were additionally able to use the phones to track  
480 consultations with sick children, make diagnoses and management choices, report key statistics to a central server,  
481 request stock from their supervising facilities, and maintain a register of patients seen. These reports were  
482 forwarded on a weekly basis to health facility supervising staff who received tailored follow-up supervision prompts.  
483 The inSCALE app also worked offline, therefore where there were network coverage issues, CHWs and health facility  
484 supervising staff had the option to delay sending of reports until they were in a location with better coverage. CHWs  
485 and supervisors were allocated to local closed user groups which enabled complimentary calls with the inSCALE  
486 smartphones to be made without charge to fellow members in the group. Finally, CHWs and their health facility  
487 supervisors received weekly (CHWs only) and monthly (CHWs and facility supervisors) automated motivational  
488 messages tailored to their report results with the tone and emphasis based on formative work. After an initial 6-  
489 month roll-out and embedding phase, the technology intervention continued to be implemented in intervention arm



490 districts for an additional 18 months. Standard care during this period was available in both intervention and control  
491 arm districts, where CHWs and health facilities provided guideline-led management for childhood illnesses via the  
492 underlying iCCM programme and integrated management of neonatal and childhood illnesses (IMNCI) services(9,54)  
493 respectively.

494 Data on CHW recruitment, training, resignations, and replacements were tracked by supervising health facilities at  
495 district level and this data was regularly extracted into the inSCALE database during the follow-up period by the  
496 study team in order to estimate attrition rates.

497

## 498 **Outcomes**

499 The primary outcome for the trial was the percentage of recent cases of MDP in the last 4 weeks in children 2  
500 months to 5 years of age that were treated using appropriate medication(15). Secondary outcomes were the  
501 prevalence of MDP in children at endline, the percentage of cases of MDP appropriately treated with recommended  
502 first line medications, the percentage of children who sought care for MDP by provider type, the percentage of  
503 CHWs who had had a stock-out of iCCM medications in the past 3 months, CHW attrition rate calculated as the  
504 proportion of CHWs who left their post during the follow-up period out of the total CHWs trained at baseline, CHW  
505 clinical knowledge scores (overall and by condition subgroup), and composite scores describing CHW enthusiasm and  
506 drive for the job (motivation) and sense of connectedness to the local and national iCCM programme (social  
507 identification). CHW knowledge scores were calculated as the sum of correct clinical decisions mentioned by the  
508 CHW in response to a series of scenarios involving children with symptoms of mild and severe disease. Points for  
509 correct items were weighted according to an algorithm defined in Supplementary file 1. CHW motivation and social  
510 identification scores were calculated by a factor analysis and empirical item reduction process applied to original  
511 field tool responses. The methods have been detailed previously(55), and resulted in a three-factor CHW motivation  
512 scale of 17 items measuring general motivation, feelings of reward for effort, and retention in role. An additional  
513 single factor CHW scale of 4 items was identified which explained the majority of the variation in social identification  
514 between CHWs. Retained items from both the motivation and social identification tools showed good internal  
515 consistency ( $\alpha = 0.67$  for CHW motivation and  $\alpha = 0.69$  for CHW social identification). The final motivation  
516 scores were calculated as the product of the rotated factor analysis regression coefficients and the Likert value for  
517 each original item. The final social identification scores were calculated as the sum of the original 4 items (after  
518 reverse coding as appropriate).

519 Additional impact measures included the percentage of children who were appropriately treated overall whether  
520 they had symptoms of one or more of MDP in the last 4 weeks (i.e. a per-child analysis), and two sensitivity analyses  
521 of the main impact outcome using alternative definitions of appropriate treatment. All definitions of appropriate  
522 treatment and medications used in primary secondary and additional endpoints are provided in Supplementary File  
523 1 (Table S8).

524

525

526

## 527 **Statistical analysis**

528 All analyses were based on intention-to-treat principles and accounted for the cluster-randomised design.

529 Multivariate mixed-effects models were specified for all impact outcomes, which account for the clustering of

530 outcomes by inclusion of a random intercept at the district level. Intervention arm, the cluster mean percentage of

531 children who were appropriately treated at baseline, and the parameters used to balance intervention arms during

532 randomisation were included as fixed effects. Unadjusted analyses of impact were also performed, and the results

533 included in supplementary file 1 (Table S1). For the primary outcome and other binary models, odds ratios were

534 converted to risk ratios using the marginal standardisation technique and 95% CIs estimated using the delta method

535 (56). Additional sensitivity analyses of the primary outcome were conducted to account for alternative treatments

536 available for MDP [see Supplementary file 1 Table S8 for definitions]. Robustness checks of the primary outcomes

537 were conducted by estimating cluster averaged results using t-tests following the procedures of Hayes and

538 Moulton(38), recommended when the number of clusters per arm is less than 10(38) [see Supplementary file 1].

539 CHW attrition was estimated using cluster-averaged mean rates as human resources information was provided at

540 this level only from district health offices. In order to estimate a pooled effect of the inSCALE technology

541 intervention on appropriate treatment across both Uganda and Mozambique, we performed a meta-analysis of

542 effect sizes by combining the results of the Mozambique (this study) and Uganda [ref] trials of the inSCALE

543 intervention. As there was no significant heterogeneity (<50% estimated from exploratory meta-analysis models)

544 between studies, we present the pooled result from a fixed effects meta-analysis.

545

546

547

548 Supplementary file Tables

Table	Caption
<b>Supplementary file 1</b>	
S1	Unadjusted analyses of primary outcomes
S2	Sensitivity analyses for primary outcome at endline (any episode of MDP): Alternative definitions of appropriate malaria treatment
S3	Whole Child Analysis – Appropriate treatment
S4a	Robustness tests (cluster-averaged outcomes) – Primary Outcomes
S4b	Robustness tests (cluster-averaged outcomes) – Secondary Outcomes: appropriate treatment stratified by condition or provider
S5	Robustness tests (cluster-averaged outcomes) – Secondary outcomes: prevalence of suspected and confirmed malaria, malaria blood testing, diarrhoea, and pneumonia
S6	CHW clinical knowledge by subgroup (diagnosis of MDP, treatment of MDP)
S7a	Item weighting – Case study: Francis/Alberte (pneumonia and diarrhoea)
S7b	Item weighting – Case study: Hope/Tina (malaria)
S7c	Item weighting – Case study: Beatrice/Janete (severe pneumonia)
S7d	Item weighting – Case study: Muteesa/Kizito (severe disease/malaria)
S7e	Item weighting – Case study: James (severe disease/malaria)
S7f	CHW Knowledge scoring for subcategories: diagnosis and treatment of suspected malaria, diarrhoea and pneumonia
S8	Definitions of appropriate treatment and other key child health outcomes
<b>Supplementary file 2</b>	
inSCALE data collection forms	

549

550

551

552 References

- 553 1. WHO. Children: improving survival and well-being [Internet]. 2020 [cited 2021 Sep 29]. Available from:  
554 <https://www.who.int/news-room/fact-sheets/detail/children-reducing-mortality>
- 555 2. UNICEF. Levels and trends in child mortality 2019: Estimates developed by the UN Inter-agency group for child  
556 mortality estimation [Internet]. 2019. Available from: [https://www.unicef.org/reports/levels-and-trends-child-](https://www.unicef.org/reports/levels-and-trends-child-mortality-report-2019)  
557 [mortality-report-2019](https://www.unicef.org/reports/levels-and-trends-child-mortality-report-2019)
- 558 3. WHO, UNICEF. WHO/UNICEF JOINT STATEMENT: Integrated Community Case Management (iCCM) [Internet].  
559 2012 [cited 2021 Sep 22]. Available from:  
560 [https://www.who.int/maternal\\_child\\_adolescent/documents/statement\\_child\\_services\\_access\\_whounicef.pdf](https://www.who.int/maternal_child_adolescent/documents/statement_child_services_access_whounicef.pdf)
- 561 4. Kallander K, Burgess DH, Qazi SA. Early identification and treatment of pneumonia: a call to action. *Lancet Glob*  
562 *Health*. 2016 Jan 1;4(1):e12–3.
- 563 5. Diaz T, Aboubaker S, Young M. Current scientific evidence for integrated community case management (iCCM)  
564 in Africa: Findings from the iCCM Evidence Symposium. *J Glob Health*. 2014 Dec;4(2):020101.
- 565 6. Boschi-Pinto C, Labadie G, Dilip TR, Oliphant N, Dalglish SL, Aboubaker S, et al. Global implementation survey of  
566 Integrated Management of Childhood Illness (IMCI): 20 years on. *BMJ Open*. 2018 Jul 1;8(7):e019079.
- 567 7. Allen KC, Whitfield K, Rabinovich R, Sadruddin S. The role of governance in implementing sustainable global  
568 health interventions: review of health system integration for integrated community case management (iCCM)  
569 of childhood illnesses. *BMJ Glob Health*. 2021 Mar 1;6(3):e003257.
- 570 8. Prosnitz D, Herrera S, Coelho H, Moonzwe Davis L, Zalisk K, Yourkavitch J. Evidence of Impact: iCCM as a  
571 strategy to save lives of children under five. *J Glob Health*. 2019 Jun;9(1):010801.
- 572 9. Oliphant NP, Manda S, Daniels K, Odendaal WA, Besada D, Kinney M, et al. Integrated community case  
573 management of childhood illness in low- and middle-income countries. *Cochrane Database Syst Rev* [Internet].  
574 2021 [cited 2021 Sep 22];(2). Available from:  
575 <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012882.pub2/full>
- 576 10. The Global Fund for HIV TB and Malaria, WHO, UNICEF. Integrated Community Case Management (iCCM) in  
577 Sub-Saharan Africa: Successes & Challenges with Access, Speed & Quality [Internet]. Nairobi, Kenya; 2018 Aug  
578 [cited 2021 Sep 30] p. 145. Available from:  
579 [https://www.theglobalfund.org/media/9754/core\\_integratedcommunitycasemanagementsub-](https://www.theglobalfund.org/media/9754/core_integratedcommunitycasemanagementsub-saharanafrica_review_en.pdf)  
580 [saharanafrica\\_review\\_en.pdf](https://www.theglobalfund.org/media/9754/core_integratedcommunitycasemanagementsub-saharanafrica_review_en.pdf)
- 581 11. WHO Global Observatory for eHealth. mHealth: new horizons for health through mobile technologies: second  
582 global survey on eHealth. 2011 [cited 2022 Feb 5]; Available from:  
583 <https://apps.who.int/iris/handle/10665/44607>
- 584 12. Braun R, Catalani C, Wimbush J, Israelski D. Community Health Workers and Mobile Technology: A Systematic  
585 Review of the Literature. Bullen C, editor. *PLoS ONE*. 2013 Jun 12;8(6):e65772.
- 586 13. Källander K, Tibenderana JK, Akpogheneta OJ, Strachan DL, Hill Z, ten Asbroek AHA, et al. Mobile Health  
587 (mHealth) Approaches and Lessons for Increased Performance and Retention of Community Health Workers in  
588 Low- and Middle-Income Countries: A Review. *J Med Internet Res*. 2013 Jan 25;15(1):e17.
- 589 14. World Bank. Mobile cellular subscriptions (per 100 people) - Sub-Saharan Africa [Internet]. 2020 [cited 2022  
590 Feb 5]. Available from: <https://data.worldbank.org/indicator/IT.CEL.SETS.P2?locations=ZG>

- 591 15. Källander K, Strachan D, Soremekun S, Hill Z, Lingam R, Tibenderana J, et al. Evaluating the effect of innovative  
592 motivation and supervision approaches on community health worker performance and retention in Uganda  
593 and Mozambique: study protocol for a randomised controlled trial. *Trials*. 2015 Apr 12;16(1):157.
- 594 16. Feldman M, Krylova VL, Farrow P, Donovan L, Zandamela E, Rebelo J, et al. Community health worker  
595 knowledge, attitudes and practices towards COVID-19: Learnings from an online cross-sectional survey using a  
596 digital health platform, UpSCALE, in Mozambique. *PLOS ONE*. 2021 Feb 10;16(2):e0244924.
- 597 17. Malaria Consortium. upSCALE mHealth system strengthening for case management and disease surveillance.  
598 2018 [cited 2021 Sep 17]; Available from: <https://www.malariaconsortium.org/upscale/>
- 599 18. Global Fund to Fight AIDS, Tuberculosis and Malaria. Global Fund Thematic Review on Community Health  
600 [Internet]. 2020 Jun [cited 2022 Feb 18] p. 46. Available from:  
601 [https://www.theglobalfund.org/media/10128/core\\_endasantecomunityhealthsynthesis\\_review\\_en.pdf](https://www.theglobalfund.org/media/10128/core_endasantecomunityhealthsynthesis_review_en.pdf)
- 602 19. Save the Children. Systems Effects of Integrated Community Case Management Projects: Mozambique Country  
603 Report [Internet]. Resource Centre. 2019 [cited 2021 Jun 11]. Available from:  
604 <https://resourcecentre.savethechildren.net/library/systems-effects-integrated-community-case-management-projects-mozambique-country-report>  
605
- 606 20. Unger CC, Salam SS, Sarker MSA, Black R, Cravioto A, Arifeen SE. Treating diarrhoeal disease in children under  
607 five: the global picture. *Arch Dis Child*. 2014 Mar 1;99(3):273–8.
- 608 21. Nsabagasani X, Ogwal-Okeng J, Mbonye A, Ssengooba F, Muhumuza S, Hansen EH. Availability and utilization of  
609 the WHO recommended priority lifesaving medicines for under five-year old children in public health facilities  
610 in Uganda: a cross-sectional survey. *J Pharm Policy Pract*. 2015 May 11;8(1):18.
- 611 22. Soremekun S, Kasteng F, Lingam R, Vassall A, Kertho E, Settumba S, et al. Variation in the quality and out-of-  
612 pocket cost of treatment for childhood malaria, diarrhoea, and pneumonia: Community and facility based care  
613 in rural Uganda. *PLOS ONE*. 2018 Nov 26;13(11):e0200543.
- 614 23. Bruxvoort K, Festo C, Kalolella A, Cairns M, Lyaruu P, Kenani M, et al. Cluster Randomized Trial of Text Message  
615 Reminders to Retail Staff in Tanzanian Drug Shops Dispensing Artemether-Lumefantrine: Effect on Dispenser  
616 Knowledge and Patient Adherence. *Am J Trop Med Hyg*. 2014 Oct 1;91(4):844–53.
- 617 24. Zurovac D, Sudoi RK, Akhwale WS, Ndiritu M, Hamer DH, Rowe AK, et al. The effect of mobile phone text-  
618 message reminders on Kenyan health workers' adherence to malaria treatment guidelines: a cluster  
619 randomised trial. *Lancet Lond Engl*. 2011 Aug 27;378(9793):795–803.
- 620 25. Friedman W, Woodman B, Chatterji M. Can mobile phone messages to drug sellers improve treatment of  
621 childhood diarrhoea?--A randomized controlled trial in Ghana. *Health Policy Plan*. 2015 Mar;30 Suppl 1:i82-92.
- 622 26. Mubiru D, Byabasheija R, Bwanika JB, Meier JE, Magumba G, Kaggwa FM, et al. Evaluation of Integrated  
623 Community Case Management in Eight Districts of Central Uganda. *PLOS ONE*. 2015 Aug 12;10(8):e0134767.
- 624 27. Marangu D, Zar HJ. Childhood pneumonia in low-and-middle-income countries: An update. *Paediatr Respir Rev*.  
625 2019 Nov;32:3–9.
- 626 28. WHO. Child mortality and causes of death [Internet]. Geneva, Switzerland; 2022 [cited 2022 Feb 18]. (Global  
627 Health Observatory). Available from: [https://www.who.int/data/gho/data/themes/topics/topic-  
628 details/GHO/child-mortality-and-causes-of-death](https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/child-mortality-and-causes-of-death)
- 629 29. Information NC for B, Pike USNL of M 8600 R, MD B, Usa 20894. Malaria transmission and antimalarial  
630 medicines [Internet]. Guidelines for the Treatment of Malaria. 3rd edition. World Health Organization; 2015  
631 [cited 2021 Sep 21]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK294437/>

- 632 30. Lam F, Wentworth L, Cherutich P, Migiro S, Abdala K, Musyoka M, et al. An evaluation of a national oral  
633 rehydration solution and zinc scale-up program in Kenya between 2011 and 2016. *J Glob Health*. 9(1):010505.
- 634 31. Nawa M. Investigating the Effect of Prompt Treatment on Malaria Prevalence in Children Aged below Five  
635 Years in Zambia: A Nested Case-Control Study in a Cross-Sectional Survey. *Adv Public Health*. 2020 Jan  
636 16;2020:e4289420.
- 637 32. Qazi S, Aboubaker S, MacLean R, Fontaine O, Mantel C, Goodman T, et al. Ending preventable child deaths from  
638 pneumonia and diarrhoea by 2025. Development of the integrated Global Action Plan for the Prevention and  
639 Control of Pneumonia and Diarrhoea. *Arch Dis Child*. 2015 Feb 1;100(Suppl 1):S23–8.
- 640 33. Campbell H, Arifeen S el, Hazir T, O’Kelly J, Bryce J, Rudan I, et al. Measuring Coverage in MNCH: Challenges in  
641 Monitoring the Proportion of Young Children with Pneumonia Who Receive Antibiotic Treatment. *PLOS Med*.  
642 2013 May 7;10(5):e1001421.
- 643 34. Eisele TP, Silumbe K, Yukich J, Hamainza B, Keating J, Bennett A, et al. Measuring coverage in MNCH: accuracy  
644 of measuring diagnosis and treatment of childhood malaria from household surveys in Zambia. *PLoS Med*.  
645 2013;10(5):e1001417.
- 646 35. Walker CLF, Fontaine O, Black RE. Measuring Coverage in MNCH: Current Indicators for Measuring Coverage of  
647 Diarrhea Treatment Interventions and Opportunities for Improvement. *PLOS Med*. 2013 May  
648 7;10(5):e1001385.
- 649 36. Demographic Health Surveys. The DHS Program - Questionnaires and Manuals [Internet]. USAID. [cited 2021  
650 Jun 11]. Available from: <https://dhsprogram.com/Methodology/Questionnaires.cfm>
- 651 37. UNICEF. Tools - UNICEF MICS [Internet]. [cited 2021 Jun 11]. Available from: <https://mics.unicef.org/tools>
- 652 38. Hayes R, Moulton L. Cluster Randomised Trials [Internet]. 2nd ed. Chapman and Hall/CRC; [cited 2021 Jun 10].  
653 Available from: [https://www.routledge.com/Cluster-Randomised-Trials/Hayes-](https://www.routledge.com/Cluster-Randomised-Trials/Hayes-Moulton/p/book/9781498728225)  
654 [Moulton/p/book/9781498728225](https://www.routledge.com/Cluster-Randomised-Trials/Hayes-Moulton/p/book/9781498728225)
- 655 39. Feroz A, Jabeen R, Saleem S. Using mobile phones to improve community health workers performance in low-  
656 and-middle-income countries. *BMC Public Health*. 2020 Jan 13;20(1):49.
- 657 40. Crul S, Diop J. The mHealth opportunity in Sub-Sahara Africa: The path towards practical application [Internet].  
658 Deloitte; 2014 [cited 2021 Sep 20]. Available from:  
659 [https://www2.deloitte.com/content/dam/Deloitte/nl/Documents/technology-media-](https://www2.deloitte.com/content/dam/Deloitte/nl/Documents/technology-media-telecommunications/deloitte-nl-mhealth.pdf)  
660 [telecommunications/deloitte-nl-mhealth.pdf](https://www2.deloitte.com/content/dam/Deloitte/nl/Documents/technology-media-telecommunications/deloitte-nl-mhealth.pdf)
- 661 41. WHO. WHO Guideline: recommendations on digital interventions for health system strengthening [Internet].  
662 World Health Organization; 2019 [cited 2021 Sep 21]. Available from:  
663 <http://www.who.int/reproductivehealth/publications/digital-interventions-health-system-strengthening/en/>
- 664 42. WHO, UNICEF. Institutionalising integrated community case management (iCCM) to end preventable child  
665 deaths: Technical consultation and country action planning 22-26 July 2019, Elilly International Hotel, Addis  
666 Ababa, Ethiopia.
- 667 43. National Institute of Statistics Mozambique. Inhambane — Instituto Nacional de Estatística [Internet]. 2013  
668 [cited 2021 Jun 11]. Available from: [http://www.ine.gov.mz/estatisticas/estatisticas-territorias-](http://www.ine.gov.mz/estatisticas/estatisticas-territorias-distribuidas/inhambane)  
669 [distribuidas/inhambane](http://www.ine.gov.mz/estatisticas/estatisticas-territorias-distribuidas/inhambane)
- 670 44. UN Inter-agency Group for Child Mortality Estimation. Under five Mortality Rate - Mozambique [Internet].  
671 [cited 2021 Jun 11]. Available from: <https://childmortality.org/data/Mozambique>

- 672 45. Fernandes QF, Wagenaar BH, Anselmi L, Pfeiffer J, Gloyd S, Sherr K. Effects of health-system strengthening on  
673 under-5, infant, and neonatal mortality: 11-year provincial-level time-series analyses in Mozambique. *Lancet*  
674 *Glob Health*. 2014 Aug;2(8):e468–77.
- 675 46. Källander K, Counihan H, Cerveau T, Mbofana F. Barriers on the pathway to survival for children dying from  
676 treatable illnesses in Inhambane province, Mozambique. *J Glob Health [Internet]*. [cited 2021 Jun 11];9(1).  
677 Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6596358/>
- 678 47. Ivers NM, Halperin IJ, Barnsley J, Grimshaw JM, Shah BR, Tu K, et al. Allocation techniques for balance at  
679 baseline in cluster randomized trials: a methodological review. *Trials*. 2012 Aug 1;13(1):120.
- 680 48. Moulton LH. Covariate-based constrained randomization of group-randomized trials. *Clin Trials Lond Engl*.  
681 2004;1(3):297–305.
- 682 49. WHO. Health facility survey : tool to evaluate the quality of care delivered to sick children attending outpatient  
683 facilities [Internet]. World Health Organization; 2003 [cited 2021 Jun 11]. Available from:  
684 <https://apps.who.int/iris/handle/10665/42643>
- 685 50. Chandler CIR, Chonya S, Mtei F, Reyburn H, Whitty CJM. Motivation, money and respect: a mixed-method  
686 study of Tanzanian non-physician clinicians. *Soc Sci Med* 1982. 2009 Jun;68(11):2078–88.
- 687 51. Franco LM, Bennett S, Kanfer R, Stubblebine P. Determinants and consequences of health worker motivation in  
688 hospitals in Jordan and Georgia. *Soc Sci Med* 1982. 2004 Jan;58(2):343–55.
- 689 52. DIMAGI. Dimagi | Technology for Social Impact [Internet]. Dimagi. [cited 2022 May 9]. Available from:  
690 <https://www.dimagi.com/>
- 691 53. Strachan DL, Källander K, Nakirunda M, Ndima S, Muiambo A, Hill Z, et al. Using theory and formative research  
692 to design interventions to improve community health worker motivation, retention and performance in  
693 Mozambique and Uganda. *Hum Resour Health*. 2015 Apr 30;13:25.
- 694 54. WHO, UNICEF, editors. Handbook IMCI: integrated management of childhood illness. Geneva: World Health  
695 Organization; 2005. 163 p. (IMCI, Integrated Management of Childhood Illness).
- 696 55. Strachan DL. Ugandan community health worker motivation: using the Social Identity Approach to explore an  
697 accepted constraint to scaled up health strategies [Internet] [Doctoral]. Doctoral thesis, UCL (University College  
698 London). UCL (University College London); 2019 [cited 2022 Feb 5]. p. 1–410. Available from:  
699 <https://discovery.ucl.ac.uk/id/eprint/10073256/>
- 700 56. Localio AR, Margolis DJ, Berlin JA. Relative risks and confidence intervals were easily computed indirectly from  
701 multivariable logistic regression. *J Clin Epidemiol*. 2007 Sep;60(9):874–82.

702



703 **Contributors**

704 SS, KK, RL, FK, ACB, AB, DS, ZH, GA, JT, NS, JC, FB, SM and BK designed and performed the study. SS analysed the  
705 data. SS, RL and KK drafted the manuscript and FK, ACB, AB, ZH, GA, JT, NS, JC, FB, SM and BK reviewed the  
706 manuscript. KK, RL, FK, DS, ZH, JT provided critical comments on the review of the manuscript. All authors have read  
707 and approved the final manuscript.

708 **Declaration of Competing Interest**

709 We declare no competing interests.

710 **Availability of study data**

711 The data for the inSCALE project is available on the public repository LSHTM Data Compass under DOI  
712 <https://doi.org/10.17037/DATA.00002559>.

713 **Funding**

714 The inSCALE study was supported by grants to JT and BK from The Bill and Melinda Gates Foundation, grant number  
715 OPP1002407. The BMGF played no role in the design, analysis, decision to publish or preparation of this manuscript.

716 **Acknowledgements**

717 We wish to thank the local research team who collected and managed the data, diMaggi for support in designing the  
718 app software, the CHWs and supervisors who delivered the intervention, and the participants of the study for their  
719 time and insight. Funding for this research was provided by the Bill & Melinda Gates Foundation [grant code  
720 OPP1002407] and UK Department for International Development (UK Aid) through grants to Malaria Consortium, the  
721 London School of Hygiene and Tropical Medicine, and the Institute for Global Health, University College London for  
722 the inSCALE project (<http://www.malariaconsortium.org/inscale/>). The funders participated in the initial discussions  
723 on intervention design but had no role in the design of the evaluation, data gathering, analysis, interpretation, or  
724 writing up of the findings. SS, KK, RL, NB, FK and BK had full access to all the data and SS had final responsibility for  
725 the decision to submit for publication.



727

728

